---
title: "Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/271950396.md"
datetime: "2026-01-08T14:36:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271950396.md)
  - [en](https://longbridge.com/en/news/271950396.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271950396.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/271950396.md) | [English](https://longbridge.com/en/news/271950396.md)


# Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation

Soligenix Inc. has released a corporate presentation outlining its progress in developing treatments for rare diseases and public health threats. The company highlights its late-stage pipeline, which includes HyBryte (SGX301) for cutaneous T-cell lymphoma with positive Phase 3 results and ongoing confirmatory studies. Other clinical-stage assets include SGX302 for psoriasis and SGX945 for Behçet’s disease, both with orphan designations. The presentation details significant funding from federal sources, including NIH contracts and grants, and estimates a total addressable global market potential of approximately $2 billion in annual sales across its portfolio. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Soligenix (SNGX.US)](https://longbridge.com/zh-HK/quote/SNGX.US.md)

## 相關資訊與研究

- [Xilio Therapeutics Updates Investor Presentation on I-O Strategy](https://longbridge.com/zh-HK/news/278392464.md)
- [IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy](https://longbridge.com/zh-HK/news/279169430.md)
- [60 Degree Announces All Patients Cured For Babesiosis With Tafenoquine](https://longbridge.com/zh-HK/news/278852432.md)
- [Arbor posts investor presentation outlining portfolio, liquidity, deleveraging and asset resolution plans](https://longbridge.com/zh-HK/news/278776771.md)
- [08:27 ETNew Study Positions Nevisense's EIS as a valuable and sensitive tool for assessing skin barrier impairment](https://longbridge.com/zh-HK/news/278555841.md)